Petra Langerbeins

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 17, 2026

Effectiveness of an on-site vaccination campaign for patients with cancer.

Effectiveness of an on-site vaccination campaign for patients with cancer.

Journal: BMC public health

Published: March 05, 2026

Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Journal: Blood

Published: December 23, 2025

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Journal: Blood

Published: December 23, 2025

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Journal: European journal of haematology

Published: December 12, 2025

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Journal: HemaSphere

Published: December 05, 2025

Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.

Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.

Journal: Blood advances

Published: May 08, 2025

The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.

The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.

Journal: Blood

Published: May 08, 2025

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Journal: Blood

Published: May 08, 2025

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Journal: Blood cancer journal

Published: March 09, 2025

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 27, 2024

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Journal: Blood

Published: September 17, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026